CTKB - CIK 0001831915
The table below shows Cytek Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.74M | -$125.00K | - | - | - | $3.96M |
| Capital expenditure | $2.17M | $849.00K | - | - | - | $567.00K |
| Investing cash flow | -$27.08M | $9.45M | - | - | - | -$5.75M |
| Dividends paid | - | - | - | - | - | - |
Cytek Biosciences, Inc. reported operating cash flow of -$4.69M for fiscal year 2025. That is down 118.5% from $25.38M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from $15.16M (FY 2020) to -$4.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | $0.00 | $10.63M | $7.00M | $11.90M | $2.70M | $0.00 |
| Financing cash flow | $3.98M | -$11.54M | - | - | - | $1.61M |